TEPEZZA ratings & reviews

Teprotumumab
Company: HZNP
Brand: TEPEZZA
Drug class: Antineoplastic and Immunomodulating Agents
+2 more
Antineoplastic and Immunomodulating Agents, Agents that Suppress the Immune System, Insulin-like Growth Factor Receptor (IGFR) Inhibitors

Sermo AI Overview

  • While Tepezza shows effective outcomes for Graves' ophthalmopathy, its adherence varies widely among patients, with a mean score of 3.8 indicating potential challenges in following the treatment regimen.
  • Concerns regarding Tepezza's side effects, particularly hearing loss, are significant. Many physicians note these risks could greatly affect patient suitability and the overall treatment experience.
  • Tepezza is generally viewed positively for treating thyroid eye disease, with a favorable efficacy profile and a high efficacy rating of 4.1. Many physicians believe it outperforms alternative treatments in terms of effectiveness and adherence.
Based on insights from Sermo’s triple verified physicians

Description

Teprotumumab-trbw is the active ingredient in TEPEZZA, which is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. It is formulated as a sterile, lyophilized powder for intravenous infusion. Each vial contains a 500 mg dose of teprotumumab-trbw along with inactive ingredients such as L-histidine, L-histidine hydrochloride monohydrate, polysorbate 20, and trehalose dihydrate.

Source: This information is sourced from FDA and powered by AI

Dosage & Administration

How should I use this medication?

This medication is injected into a vein. It is usually given by a care team in a hospital or clinic setting. Talk to your care team about the use of this medication in children. Special care may be needed.

Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once. NOTE: This medicine is only for you. Do not share this medicine with others.

What if I miss a dose?

It is important not to miss your dose. Call your care team if you are unable to keep an appointment.

Where should I keep my medication?

This medication is given in a hospital or clinic. It will not be stored at home.

NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.

Side Effects

What side effects may I notice from receiving this medication?

Side effects that you should report to your care team as soon as possible: -Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat -High blood sugar (hyperglycemia)—increased thirst or amount of urine, unusual weakness or fatigue, blurry vision -Infusion reactions—chest pain, shortness of breath or trouble breathing, feeling faint or lightheaded Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome): -Dry skin -Hair loss -Hearing loss -Heavy periods -Irregular menstrual cycles or spotting -Menstrual cramps -Nausea

This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings & Precautions

What should I tell my care team before I take this medication?

They need to know if you have any of these conditions: -Diabetes -Inflammatory bowel disease -An unusual or allergic reaction to teprotumumab, other medications, foods, dyes, or preservatives -Pregnant or trying to get pregnant -Breast-feeding

What may interact with this medication?

Interactions have not been studied.

This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.

What should I watch for while using this medication?

Visit your care team for regular checks on your progress. Tell your care team if your symptoms do not start to get better or if they get worse. Talk to your care team if you or your partner wish to become pregnant or think either of you might be pregnant. This medication can cause serious birth defects if taken during pregnancy or for 6 months after stopping therapy. This medication may increase blood sugar. The risk may be higher in patients who already have diabetes. Ask your care team what you can do to lower your risk of diabetes while taking this medication. This medication can cause serious infusion reactions. To reduce the risk, your care team may give you other medications to take before receiving this one. Be sure to follow the directions from your care team.

Source: This information is sourced from Elsevier Inc.

Disclaimer

The reviews, ratings, comments, and opinions expressed on this platform are solely those of the individual medical professionals who posted them and do not reflect the views or positions of Sermo, Inc. Sermo does not endorse, verify, or validate the content of individual reviews. The information provided is user-generated and reflects personal clinical experiences, which may not be complete, accurate, or applicable to your specific health needs. It is not intended as medical advice.

Prescription medications affect individuals differently, and what works for one person may not work for another. Always consult your doctor, pharmacist, or other qualified healthcare provider to ensure the information displayed applies to your personal circumstances. Only a licensed healthcare provider can advise you on what is safe and effective for you.

Keep all medications out of the reach of children, never share your medicine with others, and use each medication only as prescribed. Your reliance on any information provided on this platform is at your own risk.

Terms of use

  1. Sermo Drug Ratings, and all information provided on this website, may not be used in combination with any artificial intelligence tool (including to train an algorithm, test, process, analyze, generate output and/or develop any form of artificial intelligence tool). 

  2. Visitors to the online patient-facing website at Sermo.com (“Sermo Drug Ratings”) are Authorized Users of the website, which contains data owned by a third-party provider, Elsevier, Inc.  Accordingly, by visiting Sermo Drug Ratings, Authorized User acknowledges that the website includes Elsevier owned data that Sermo licenses pursuant to a separate usage and Data agreement (the “Agreements”).  Authorized User further acknowledges that Sermo is a third-party beneficiary of the Agreements and Authorized User’s use of the website hereby binds them to the terms of the Agreements; provided, however, that Elsevier shall have no obligations or liability to an Authorized User whatsoever pursuant to the terms of the Agreements.

Welcome to Sermo's Drug Ratings

Previously only for members, Sermo Drug Ratings are now openly available to all healthcare providers, patients, and industry professionals to support better healthcare decisions.

Clinical expertise
Insights based on real prescribing experience from triple-verified practicing physicians only
Detailed insights
Ratings on key attributes including efficacy, safety, tolerability, accessibility, and adherence
Unbiased reviews
Independent, physician-only reviews, free from pharmaceutical industry influence